In patient-derived xenografts, CXCR4 inhibitors AMD3100 and TN14003 block tumor growth and metastasis in both herceptin-sensitive and herceptin-resistant HER2+ breast cancer. This evidence concerns the gene CXCR4 and breast carcinoma.